Patients enrolled into Phase III diabetic retinopathy drug trial

Article

Vitreoretinal Technologies, Inc has begun to enrol and treat diabetic retinopathy patients in the clinical trial for its pharmaceutical treatment Vitreosolve.

Vitreoretinal Technologies, Inc has begun to enrol and treat diabetic retinopathy patients in the clinical trial for its pharmaceutical treatment Vitreosolve.

Vitreosolve, a small molecule currently used for vitreous liquefaction as an adjunct to pars plana vitrectomy surgery, is now being evaluated as a preventative treatment for diabetic retinopathy. There are currently no approved pharmaceutical treatments indicated for this condition.

The multinational Phase III trial, investigating safety and efficacy, is the first of two studies required for a New Drug Application (NDA) to be granted by the FDA. Patients are currently being enrolled and treated in India and the US.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
© 2025 MJH Life Sciences

All rights reserved.